Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are associated with right ventricular structure and function: The MESA-RV Study

Biomarkers

Volumn 15, Issue 8, 2010, Pages 731-738

  Kawut, Steven M ^a   Barr, R Graham ^b   Johnson, W Craig ^c   Chahal, Harjit ^d   Tandri, Harikrishna ^d   Jain, Aditya ^d   Bristow, Michael R ^e   Kizer, Jorge R ^f   Bagiella, Emilia ^b   Lima, Joao A C ^d   Bluemke, David A ^g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f WEILL CORNELL MEDICAL CENTER   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Hypertension; Inflammation; Pulmonary; Thrombosis

Indexed keywords

CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; STROMELYSIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; FEMALE; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE ENDDIASTOLIC VOLUME; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE MASS; HEART STROKE VOLUME; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY;

BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEART VENTRICLES; HUMANS; MAGNETIC RESONANCE IMAGING; MATRIX METALLOPROTEINASE 9; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES;

EID: 78649309274     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2010.516455     Document Type: Article

References (27)

1. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR. (2006). Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113:2089-96.
2. Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, Szklo M, Lima JA. (2008). Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 51:1775-83.
3. Bakouboula B, Morel O, Faure A, Zobairi F, Jesel L, Trinh A, Zupan M, Canuet M, Grunebaum L, Brunette A, Desprez D, Chabot F, Weitzenblum E, Freyssinet JM, Chaouat A, Toti F. (2008). Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med 177:536-43.
4. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR, Jr., Kronmal R, Liu K, Nelson JC, O'Leary D, Saad M F, Shea S, Szklo M, Tracy RP. (2002). Multiethnic study of atherosclerosis: objectives and design. Am J Epidemiol 156:871-81.
5. Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, and Folsom AR. (2008). The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 52:2148-55.
6. Cantini-Salignac C, Lartaud I, Schrijen F, Atkinson J, Chabot F. (2006). Metalloproteinase-9 in circulating monocytes in pulmonary hypertension. Fundam Clin Pharmacol 20:405-10.
7. Chahal H, Johnson W, Tandri H, Jain A, Hundley W, Barr R, Kawut S, Lima JA, Bluemke DA. (2010). Cardiovascular risk factors in relationship to right ventricular structure and function by MRI: the MESA-Right Ventricle study. Am J Cardiol 106:110-16.
8. Chong AY, Freestone B, Patel J, Lim HS, Hughes E, Blann AD, & Lip GY. (2006). Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 97:671-5.
9. Christ G, Graf S, Huber-Beckmann R, Zorn G, Lang I, Kneussi M, Binder BR, Huber K. (2001). Impairment of the plasmin activation system in primary pulmonary hypertension: evidence for gender diferences. Tromb Haemost 86:557-62.
10. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. (1995). Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 41:264-70.
11. Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I &, Collen D. (1988). Measurement of plasminogen activator inhibitor 1 in biologic fuids with a murine monoclonal antibodybased enzyme-linked immunosorbent assay. Blood 71:220-5.
12. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. (2001). Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103:2055-9. (Pubitemid 32373007)
13. Diebold I, Djordjevic T, Hess J, Gorlach A. (2008). Rac-1 promotes pulmonary artery smooth muscle cell proliferation by upregulation of plasminogen activator inhibitor-1: role of NFkappaB-dependent hypoxia-inducible factor-1alpha transcription. Tromb Haemost 100:1021-8.
14. Hankinson J, Kawut S, Shahar E, Smith L, Stukovsky K, Barr R. (2009). Performance of ATS-recommended spirometry reference values in a multiethnic sample of adults: The MESA-Lung Study. Chest 137:138-45.
15. Heckbert SR, Post W, Pearson GD, Arnett DK, Gomes AS, Jerosch-Herold M, Hundley WG, Lima JA, Bluemke DA. (2006). Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multiethnic Study of Atherosclerosis. J Am Coll Cardiol 48:2285-92.
16. Hoeper MM, Sosada M, Fabel H. (1998). Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 12:1446-9.
17. Hofman EA, Jiang R, Baumhauer H, Brooks MA, Carr JJ, Detrano R, Reinhardt J, Rodriguez J, Stukovsky K, Wong ND, Barr RG. (2009). Reproducibility and validity of lung density measures from cardiac CT Scans - The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. Acad Radiol 16:689-99.
18. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D. (1995). Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151:1628-31.
19. Martin I, Humbert M, Marfaing-Koka A, Capron F, Wolf M, Meyer D, Simonneau G, Angles-Cano E. (2002). Plasminogen activation by blood monocytes and alveolar macrophages in primary pulmonary hypertension. Blood Coagul Fibrinolysis 13:417-22.
20. Natori S, Lai S, Finn JP, Gomes AS, Hundley WG, Jerosch-Herold M, Pearson G, Sinha S, Arai A, Lima JA, Bluemke DA. (2006). Cardiovascular function in multi-ethnic study of atherosclerosis: normal values by age, sex, and ethnicity. AJR Am J Roentgenol 186: S357-65.
21. Pinsky DJ, Liao H, Lawson CA, Yan SF, Chen J, Carmeliet P, Loskutof DJ, Stern DM. (1998). Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 102:919-28.
22. Sanchez O, Marcos E, Perros F, Fadel E, Tu L, Humbert M, Dartevelle P, Simonneau G, Adnot S, Eddahibi S. (2007). Role of endotheliumderived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 176:1041-7. (Pubitemid 350127849)
23. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, Sutherland P, Wilson PW, Vasan RS. (2004). Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109:2850-6. (Pubitemid 38786446)
24. Umar S, Hessel M, Steendijk P, Bax W, Schutte C, Schalij M, van der Wall E, Atsma D, van der Laarse A. (2007). Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension. Pathol Res Pract 203:863-72.
25. Velagaleti RS, Gona P, Levy D, Aragam J, Larson MG, Tofler GH, Lieb W, Wang TJ, Benjamin EJ, Vasan RS. (2008). Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation 118:2252-8.
26. Vieillard-Baron A, Frisdal E, Eddahibi S, Deprez I, Baker AH, Newby AC, Berger P, Levame M, Raffestin B, Adnot S, d'Ortho MP. (2000). Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats. Circ Res 87:418-25.
27. White RJ, Meoli D F, Swarthout R F, Kallop DY, Galaria, II, Harvey JL, Miller CM, Blaxall BC, Hall CM, Pierce RA, Cool CD, Taubman MB. (2007). Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 293: L583-90.